Opioids slow and can stop breathing by suppressing the brainstem circuits that generate your breathing rhythm. They do this at multiple levels: quieting the neurons that set your respiratory pace, reducing the drive to breathe in response to rising carbon dioxide, and relaxing the muscles that keep your airway open. A breathing rate below 8 to 10 breaths per minute, or oxygen saturation dropping below 90%, are the clinical markers of opioid-induced respiratory depression.
The Brainstem’s Breathing Pacemaker
Your breathing rhythm originates in a cluster of neurons in the lower brainstem called the preBötzinger complex. This region acts as the pacemaker for inspiration, firing in a repeating cycle that tells your diaphragm and chest muscles when to contract. Opioids bind to mu-opioid receptors on and around these neurons, disrupting that cycle.
At least four brainstem regions are involved in how opioids alter breathing: the preBötzinger complex, the parabrachial/Kölliker-Fuse complex (which coordinates the transition between inhaling and exhaling), the nucleus tractus solitarius (which relays information from oxygen and carbon dioxide sensors), and the caudal medullary raphe. When opioids act on all four simultaneously, the result is a broad suppression of the brain’s ability to regulate every phase of the breathing cycle.
What Happens Inside the Neuron
When an opioid molecule locks onto a mu-opioid receptor, it triggers a chain of events inside the cell. The receptor activates a signaling protein that opens potassium channels in the neuron’s membrane. Potassium ions flow outward, making the inside of the cell more negative, a state called hyperpolarization. A hyperpolarized neuron is harder to activate, so it fires less often or stops firing altogether.
The same signaling protein also blocks a type of calcium channel that neurons need to release neurotransmitters. Without calcium flowing in at the nerve terminal, the cell can’t release its chemical messengers. Research published in the Journal of Neuroscience demonstrated that opioids specifically reduce the release of glutamate, the main excitatory neurotransmitter in the preBötzinger complex, while leaving the inhibitory neurotransmitter GABA unaffected. The net effect is that the excitatory signals driving each breath get weaker, while the inhibitory signals remain at full strength. Breathing slows, becomes shallower, and at high enough doses, stops.
Reduced Drive to Breathe
Under normal conditions, your body has a powerful safety mechanism: when carbon dioxide builds up in your blood, chemoreceptors trigger an urgent signal to breathe harder. Opioids blunt this response substantially. Even as carbon dioxide rises to dangerous levels, the brainstem fails to ramp up breathing the way it normally would. This is why opioid overdose can progress so quickly from shallow breathing to no breathing at all. The alarm system that should wake you up or force deeper breaths has been chemically muted.
Upper Airway Collapse
Opioids don’t just slow your breathing rate. They also weaken the muscles that hold your throat open. The genioglossus, the main muscle of the tongue and a critical airway dilator, loses tone when opioids act on the nerve center that controls it. Research in rats showed a dose-related suppression of this muscle’s activity when opioids were applied directly to its controlling nerve cluster.
For most people, this muscle relaxation alone isn’t enough to block the airway. But for anyone with an already narrow airway, particularly people with obstructive sleep apnea, the combination can be dangerous. The airway partially or fully collapses, and because opioids have also suppressed the carbon dioxide alarm, the arousal response that would normally wake someone up and restore muscle tone may never come. This triple threat of reduced muscle tone, blunted breathing drive, and impaired arousal is what makes opioids particularly risky during sleep or sedation.
Why Mixing With Other Sedatives Is So Dangerous
Combining opioids with benzodiazepines (such as diazepam or alprazolam) is one of the strongest predictors of fatal respiratory depression. These two drug classes suppress breathing through different mechanisms: opioids act on mu-opioid receptors, while benzodiazepines enhance the effects of GABA at a completely separate receptor type. When both are present, the interaction on breathing isn’t simply additive. It’s synergistic.
Studies combining buprenorphine (an opioid) with diazepam found that the effect on breathing was significantly greater than what either drug produced alone, and greater than what you’d expect from simply adding their individual effects together. The combination reduced both the time spent exhaling and the volume of each breath through non-additive mechanisms. Importantly, reversing either drug with its specific antidote partially blocked the respiratory depression, confirming that both drug pathways contribute simultaneously. The combination also decreased diaphragm contraction strength, a direct hit to the mechanical act of breathing itself.
Who Is Most at Risk
Certain conditions make opioid-induced respiratory depression far more likely. The PRODIGY trial and related hospital research identified several tiers of risk. Strong predictors include heart failure, kidney disease, cerebrovascular disease, recent substance use disorder, bipolar disorder or schizophrenia, and concurrent use of benzodiazepines or antidepressants. Moderate predictors include sleep apnea, chronic lung disease, and taking high daily opioid doses or long-acting formulations.
Other consistently identified risk factors from surgical settings include age over 60, female sex, obesity, diabetes, deep sedation, opioid naivety (meaning no recent opioid use, so no tolerance), and having two or more coexisting health conditions. Opioid-naive individuals are especially vulnerable because their brainstem neurons have not adapted to the presence of opioids, so even standard doses can produce profound respiratory suppression.
How Naloxone Reverses the Process
Naloxone works by competing directly with opioid molecules for the mu-opioid receptor. It has a higher affinity for the receptor than most opioids, so it physically displaces them from the binding site. Once naloxone occupies the receptor, the potassium channels close, calcium channels reopen, glutamate release resumes, and the breathing pacemaker neurons begin firing normally again.
The dose needed depends on what opioid is involved. For someone known to be opioid-dependent, very small initial doses (0.04 to 0.1 mg intravenously) can restore breathing without triggering severe withdrawal. For someone without opioid dependence, a typical starting dose is 0.4 mg. In emergencies involving synthetic opioids like fentanyl or carfentanil, much larger doses are often necessary, sometimes 10 mg or more total, because these drugs bind tightly and are present in large quantities. The nasal spray version delivers 4 mg per spray and can be repeated in alternating nostrils every 2 to 3 minutes.
One critical limitation: naloxone wears off faster than many opioids, typically within 30 to 90 minutes. This means breathing can stop again after the naloxone is metabolized but the opioid remains active. Repeated dosing or medical monitoring is essential after any reversal.